Pipeline

Responding to the emerging market needs

As our company grows, our product range expands. Responding to the emerging market needs, we are currently working on a bevy of projects with many products at the final stages of development. As soon as the final product analysis take place, we will be able to proceed with registrations.

wdt_ID Molecule Form Strength Therapeutic Area Expected Launch
1 CHOLECALCIFEROL (VITAMIN D3) Hard Liquid Capsule 10000 IU, 25000 IU D3 Deficiency Available
2 MAGNESIUM ASPARTATE Monodose Oral Solution 243 mg / 10ml Vial Magnesium Deficiency Available
3 MAGNESIUM ASPARTATE Oral Solution 243 mg / 10ml Magnesium Deficiency Available
4 OCTENIDINE HYDROCHLORIDE PHENOXYETHANOL Cutaneous Solution 0.1 % w/w. 2.0% w/w Antiseptic Q1-2020
5 TORASEMIDE Injectable Solution 10mg / 1 ml Diuretics Q2-2020
14 TORASEMIDE Tablets Tablets Q2-2020
15 FLUTICASONE PROPIONATE +SALMETEROL XINAFOATE MDI, Metered -Dose Inhaler MDI, Metered -Dose Inhaler Asthma & COPD Q4-2020
16 FLUTICASONE PROPIONATE +SALMETEROL XINAFOATE MDI, Metered -Dose Inhaler 250mcg +25 mcg /120 Doses Asthma & COPD Q4-2020
17 BUDESONIDE + FORMETEROL MDI, Metered -Dose Inhaler 80mcg +4.5 mcg Asthma & COPD Q4-2020
18 BUDESONIDE + FORMETEROL MDI, Metered -Dose Inhaler 160mcg +4.5 mcg Asthma & COPD Q4-2020